Navigation Links
U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica
Date:1/7/2008

The University of Massachusetts Medical School and the Carnegie Institution of Washington announced today that they have entered into licensing agreements with Oxford BioMedica (LSE: OXB), a gene therapy company, that grants the company rights to key RNA interference (RNAi) patent rights.

The technology was invented by Nobel-prize winning scientists Andrew Z. Fire, PhD, and Craig C. Mello, PhD, and their colleagues. The seminal patent claiming this technology was first granted in the United States by the United States Patent and Trademark Office in 2003. Additional patent rights have been issued in Australia and other US and foreign applications are pending.

This seminal patent covers a process by which ribonucleic acid (RNA), the cellular material responsible for the transmission of genetic information, can silence a targeted gene within a living cell. The process, called RNA interference (RNAi), can shut down disease-causing genes or direct researchers to pathways for effective drug development.

Under the terms of the license agreements, Oxford BioMedica obtains non-exclusive rights in accordance with the established licensing program of the Carnegie Institution and the University of Massachusetts Medical School, as well as certain exclusive rights for human gene therapy applications of RNA interference using lentiviral vectors. A lentiviral vector is based on a type of virus that infects dividing and nondividing cells and stores its genetic information on a single-strand of RNA instead of the more usual double-stranded DNA. In exchange, Oxford BioMedica will pay an upfront payment, annual maintenance fees, milestone payments, and royalties on sales. Further details were not disclosed.

James P. McNamara, PhD, Executive Director of the Office of Technology Management of the University of Massachusetts Medical School commented: As the Medical School looks toward the convergence of RNAi, gene therapy, and cellular therapy, including stem cells as medical treatments, the potential drug development opportunities presented by Oxfords lentiviral vector delivery technology is intriguing to us. We have structured these license agreements to help the company pursue novel applications of RNA interference based on their established broad IP in the lentiviral vector delivery space. Our hope is to see the further advancement of the RNAi field toward novel therapies in the public interest.

To date, the Carnegie Institution, acting upon behalf of itself and the University of Massachusetts Medical School under an interinstitutional agreement, has granted approximately 50 non-exclusive licenses to companies using this invention.

All rights granted under the licensing agreements with Oxford BioMedica are subject to the concurrent rights of the existing non-exclusive licensees. The Carnegie Institution and the University of Massachusetts Medical School further anticipate continuing to issue new licenses for research and other purposes in this promising field.

The University of Massachusetts Medical School and the Carnegie Institution of Washington have entered into these agreements to promote the fullest development of the patent rights with anticipated benefits to the general public.


'/>"/>

Contact: Gary Kowalczyk
gkowalczyk@ciw.edu
202-939-1118
Carnegie Institution
Source:Eurekalert

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will feature ... Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ... how to continue to feed a growing nation. At the same time, many of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments ... consulting, Nanoscience Analytical offers a broad range of contract analysis services for ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial ... Investigator, Dana-Farber Cancer Institute. The event is free and open to the public, ...
Breaking Biology Technology: